TIS tissue therapies limited

well, page-7

  1. 1,858 Posts.
    Judging by comments such as
    "CE Mark (EU) approval expected late 2012"
    and
    "CE Mark expected shortly"

    it sounds like SM doesn't expect the referral to MHRA to impose a significant time barrier, considering we're already in "late 2012".

    Interesting report. Thanks SM.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.